Strata Critical Medical annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Strata Critical Medical Stock-Based Compensation Growth & History (SRTA)
Strata Critical Medical's stock-based compensation was $17.8M for fiscal 2025.
View full Strata Critical Medical company overviewStrata Critical Medical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $17.8M | −$2.1M | −10.36% |
| 2024 | 2024-12-31 | $19.9M | $7.4M | +59.13% |
| 2023 | 2023-12-31 | $12.5M | $4.2M | +51.03% |
| 2022 | 2022-12-31 | $8.3M | — | — |
| 2021 | 2021-09-30 | $9.6M | $9.1M | +1863.47% |
| 2020 · Sep 30 | 2020-09-30 | $490,000 | $173,000 | +54.57% |
| 2019 · Sep 30 | 2019-09-30 | $317,000 | — | — |
Strata Critical Medical quarterly stock-based compensation
Q1.21
Q2.21
Q4.21
Q1.22
Q2.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | −$1.6M | −30.72% |
| Q1 2026 | 2026-03-31 | $5.0M | $818,000 | +19.40% |
| Q4 2025 | 2025-12-31 | $6.6M | $2.1M | +45.51% |
| Q3 2025 | 2025-09-30 | $1.7M | −$3.7M | −68.90% |
| Q2 2025 | 2025-06-30 | $5.3M | −$298,000 | −5.28% |
| Q1 2025 | 2025-03-31 | $4.2M | −$101,000 | −2.34% |
| Q4 2024 | 2024-12-31 | $4.5M | $1.4M | +43.55% |
| Q3 2024 | 2024-09-30 | $5.4M | $2.1M | +62.22% |
| Q2 2024 | 2024-06-30 | $5.6M | $2.9M | +101.89% |
| Q1 2024 | 2024-03-31 | $4.3M | $1.1M | +34.06% |
| Q4 2023 | 2023-12-31 | $3.2M | $503,000 | +18.98% |
| Q3 2023 | 2023-09-30 | $3.3M | $1.6M | +97.63% |
| Q2 2023 | 2023-06-30 | $2.8M | $953,000 | +51.68% |
| Q1 2023 | 2023-03-31 | $3.2M | $1.1M | +53.53% |
| Q4 2022 | 2022-12-31 | $2.6M | −$281,000 | −9.59% |
| Q3 2022 · Sep 30 | 2022-09-30 | $1.7M | −$2.2M | −57.06% |
| Q3 2022 · Jun 30 | 2022-06-30 | $1.8M | −$674,000 | −26.77% |
| Q2 2022 | 2022-03-31 | $2.1M | $194,000 | +10.19% |
| Q1 2022 | 2021-12-31 | $2.9M | — | — |
| Q4 2021 | 2021-09-30 | $3.9M | — | — |
| Q2 2021 | 2021-06-30 | $2.5M | — | — |
| Q1 2021 | 2021-03-31 | $1.9M | — | — |
Strata Critical Medical stock-based compensation trends
Between the periods ended 2019-09-30 and 2025-12-31, Strata Critical Medical's stock-based compensation increased from $317,000 to $17.8M, a change of $17.5M. The latest reported quarter, Q2 2026, shows $3.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Strata Critical Medical source filings ↗